CAMP4 Therapeutics Corporation Common Stock CAMP
Analyst Ratings
- Consensus
- Buy — 6 Buy · 0 Hold · 0 Sell (6 analysts)
- Avg. Price Target
- $8.92 (+99.0% upside)
Key Stats
- Today's Range
- $4.33 – $4.64
- 50-Day Range
- $2.90 – $6.00
- 52-Week Range
- $1.32 – $7.75
- Volume
- 50K shs
- Average Volume
- 270K shs
- Market Cap
- $281.76 million
- P/E Ratio
- —
- Dividend Yield
- —
Valuation
- P/E Ratio
- —
- Price / Book
- -406.58
- Price / Sales
- 66.83
Short Interest
- Short Interest
- 2.82%
- Days to Cover
- 3.02
Financials (TTM)
- Revenue
- $4.22 million
- Net Income
- $-107,244,000
- Net Margin
- -2543.74%
- Return on Equity
- 15475.32%
- Debt-to-Equity
- —
About CAMP4 Therapeutics Corporation Common Stock
Camp4 Therapeutics Corp is a clinical-stage biopharmaceutical company pioneering the discovery and development of regulatory RNA-based therapeutics to upregulate gene expression and restore healthy protein levels to treat various genetic diseases. The company focuses on genetic diseases of the central nervous system and liver. Its pipeline products include CMP-CPS-001 and CMP-SYNGAP. The company operates as a single operating segment, R&D, which engages in the development of a new class of RNA-based therapeutics to treat a broad range of genetic diseases.
Related Stocks
Compare head-to-head: CAMP vs LLY·CAMP vs JNJ·CAMP vs ABBV·CAMP vs ABT
Price and fundamental data are delayed and provided for informational purposes only. Not investment advice. See our disclaimer.